Stan Watowich

Stan Watowich

Company: Ridgeline Therapeutics

Job title: Founder & Chief Executive Officer


Correcting Dysregulated Fat Metabolism: Unraveling a Novel Approach to Reverse Obesity, NASH & Type 2 Diabetes 2:00 pm

Leveraging an oral small molecule therapeutic to sustainably modulate adipose tissue metabolism Targeting the root cause: preventing or reversing fatty liver disease and the progression to NASH Obesity, NASH, and T2D: interrogating animal studies and translation to the clinicRead more

day: Day 1 Stream 1 PM

Panel Discussion: Reflecting on the Last 3 Years in NASH: Is there a Horizon Beyond the Setbacks? 11:30 am

What has worked and what hasn’t? Do we need a new normal in trial design and clinical development for NASH? Adapting mindsets: how do we ‘fail earlier’ to accelerate the pathway to successful therapies?Read more

day: Day 1 Stream 2 AM

© Copyright 2022 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.